Papers/PMID:24445038
Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial.
The Journal of nutritional biochemistry2014The record
3 findings drawn from this paper, on 1 compound across 3 endpoints.
What it reported
How to read these marksWhat moved
3 findings
curcumin — increases serum adiponectin
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Findingreplicated ×2“Our results showed that curcumin intervention significantly reduced pulse wave velocity, increased level of serum adiponectin and decreased level of leptin.”
Quoted verbatim from Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial.. - Study
- RCT
- Duration
- 6 months
- Population
- adults with type 2 diabetes
Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial.2014PMID:24445038
curcumin — decreases serum leptin
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Findingreplicated ×2“Our results showed that curcumin intervention significantly reduced pulse wave velocity, increased level of serum adiponectin and decreased level of leptin.”
Quoted verbatim from Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial.. - Study
- RCT
- Duration
- 6 months
- Population
- adults with type 2 diabetes
Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial.2014PMID:24445038
curcumin — decreases pulse wave velocity (segment unspecified)
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Finding“Our results showed that curcumin intervention significantly reduced pulse wave velocity, increased level of serum adiponectin and decreased level of leptin.”
Quoted verbatim from Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial.. - Study
- RCT
- Duration
- 6 months
- Population
- adults with type 2 diabetes
Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial.2014PMID:24445038